---
title: "Cell Processor"
ocid: "ocds-r6ebe6-0000553857"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000553857"
markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000553857.md"
json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000553857.json"
source: "Public Contracts Scotland"
current_stage: "Award"
buyer: "SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE"
published: "2018-08-15"
---

# Cell Processor

Buyer: SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE  
Current stage: Award  
OCID: ocds-r6ebe6-0000553857

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000553857)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000553857.json)

## Summary

The Scottish National Blood Transfusion Service is currently engaged in a procurement process to acquire an Integrated Cell Processor, essential for completing a clinical study and subsequently for large-scale manufacturing of cell products for pivotal clinical trials. The procurement, which falls under the health industry category, is at the award stage, having signed the contract on 3rd August 2018, with a total contract value of £125,000. The delivery is set to take place in Edinburgh, Scotland, and the procurement method followed was a limited procedure, negotiated without prior publication of a competition notice.

This tender presents significant opportunities for businesses specialising in advanced therapeutic technologies, particularly those that manufacture or supply medical devices that align with the requirements of the Scottish National Blood Transfusion Service. Companies focusing on innovative medical equipment that can automate CD14+ monocyte selection or those capable of fulfilling stringent regulatory standards would be particularly well-suited to participate in future tenders within this domain. Engaging in such contracts can enable these businesses to showcase their products in a critical healthcare setting, potentially leading to further collaborations and growth opportunities.

## Notice

SNBTS require to purchase a an Integrated Cell Processor" to complete a current clinical study. On completion of the current study SNBTS will manufacture large volumes of cell product for a pivotal clinical trial using the device. Two new critical advanced therapeutics products (EBV CTL bank and Improved Islet isolation) also require the use of a cell processor.

### Lot Information

Lot 1

SNBTS require to purchase a cell processor which is able to carry out automated CD14+ monocyte selection in a fully functionally closed CE-marked system. This is a major component of our MHRA-licensed MACTH clinical trial in cirrhosis. The equipment must also carry out the IFN-Gamma Cytokine Capture System (CCS) process. This is a vital manufacturing step in our improved process for the manufacture of Epstein Barr Virus-Specific T cells (EBV CTL).

### Procurement Information

This procurement will follow Regulation 33 of the Procurement rules: negotiated procedure without prior publication. --(1) A contracting authority may award a public contract following negotiated procedure without prior publication of a contract notice or prior information notice in any of the following cases-- (b) where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons-- (i)the aim of the procurement is the creation or acquisition of a unique work of art or artistic performance; (ii) competition is absent for technical reasons; (iii)the protection of exclusive rights, including intellectual property rights, but only, in the case of paragraphs (ii) and (iii), where no reasonable alternative or substitute exists and the absence of competition is not the result of an artificial narrowing down of the parameters of the procurement;

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Public Contracts Scotland |
| Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG328394 |
| Notice type | OJEU - F15 - Voluntary Ex Ante Transparency Notice |
| Procurement type | Standard |
| Procurement category | Goods |
| Procurement method | Limited |
| Procurement method details | Award procedure without prior publication of a call for competition |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 15 Aug 2018 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 3 Aug 2018 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £125,000 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Not specified |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE |
| Locality | EDINBURGH |
| Post town | Edinburgh |
| Postcode | EH14 4BE |
| Country | Scotland |
| ITL 1 | TLM Scotland |
| ITL 2 | TLM1 East Central Scotland |
| ITL 3 | TLM13 City of Edinburgh |
| Local authority | City of Edinburgh |
| Electoral ward | Pentland Hills |
| Westminster constituency | Edinburgh South West |
| Delivery location | TLM75 City of Edinburgh |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | MILTENYI BIOTEC |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33000000 - Medical equipments, pharmaceuticals and personal care products

## Release History

- 15 Aug 2018 at 00:00 - Award - OJEU - F15 - Voluntary Ex Ante Transparency Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG328394

## Documents

- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG328394
  Cell Processor - SNBTS require to purchase a an Integrated Cell Processor" to complete a current clinical study. On completion of the current study SNBTS will manufacture large volumes of cell product for a pivotal clinical trial using the device. Two new critical advanced therapeutics products (EBV CTL bank and Improved Islet isolation) also require the use of a cell processor.

## Notice URLs

- http://
- http://www.scotblood.co.uk/
- https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000553857

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000553857. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000553857.json.